ABSTRACT
Here analyzes how the educational system of the province of Santa Fe overpass the pandemic since March 2020. It provides a general picture of the characteristics of households, their previous conditions to this crisis and some pre-existing trends in the educational system before the crisis that COVID-19 would unleash worldwide. The characteristics assumed by school continuity in 2020 and 2021 from official surveys and the working conditions of teaching. The relationship between the opening of schools and infections throughout 2021 is also presented. It works with official documents produced by the Ministry of Education and Health of the nation and the province, data from the provincial government, surveys and union reports, systematized information from local newspapers. The difficulty in preparing a detailed situation table is shown given the absence of systematically collected inputs. There are some issues that should be monitored. © 2022 Seccion Historia. Instituto Superior del Profesorado 'Eduardo Lafferriere'. All rights reserved.
ABSTRACT
This article analyzes the way in which children and adolescents went through schooling, particularly in single-mother households, during the COVID-19 pandemic. The scarce official information published is reconstructed and compiled, specific cross-check are made through the official microdata base and different documents produced by international organizations, particularly UNICEF, are selected. A quantitative and qualitative (that is, mixed) analysis is combined here, based on the work with the aforementioned sources. It is expected to provide inputs for decision-making while at the same time providing material that contributes to the field of work on school inequality that was generated during the pandemic. The general question guiding this work is to what extent the COVID-19 pandemic will deepen pre-existing marks in the educational system and what is the schooling gap by gender that the pandemic will leave behind.
ABSTRACT
OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients' adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before the outbreak of COVID-19 and was carried out during the pandemic period. The aim was to evaluate the efficacy and safety of a single oral dose NEPA plus 12 mg of dexamethasone (DEX) in patients treated with Folfoxiri plus Bevacizumab and Folfirinox. The patients were diagnosed with advanced colorectal cancer (CRC) or advanced pancreatic ductal adenocarcinoma (PDAC). They were divided into two groups: naïve patients and patients previously treated with serotonin receptor antagonists (5HT3-RA) and neurokin-1 receptor antagonists (NK1-RA). RESULTS: During the overall phase, the complete response (CR) rate was 96.8% in naïve patients treated with Folfoxiri plus Bevacizumab, and 94.6% in patients treated with Folfirinox. During the acute and delayed phases, the CR rate was 92.8% and 94.2%, with Folfoxiri and Bevacizumab, as well as 96.2% and 94.6%, with Folfirinox. There was no adequate control of CINV events in patients on antiemetic prophylaxis with 5HT3-RA or NK1-RA associated with cortisone. During the overall phase, the CR rate was 74.6% with Folfoxiri plus Bevacizumab and 75.8% with Folfirinox. During the acute and delayed phases, the CR rate was 72.5% and 74.8% with Folfoxiri plus Bevacizumab, as well as 75.2% and 74.6% with Folfirinox. CONCLUSIONS: This study has shown the therapeutic benefits of NEPA in the management and prophylaxis of CINV events, both in naive patients and patients previously treated with 5HT3-RA and NK1-RA. In addition, NEPA has been shown to be safe, both before and during the COVID-19 pandemic.